[Treatment of hyperkeratotic dermatoses with an oral aromatic retinoid (Ro 10-9359)].
Treatment with an oral aromatic all-trans retinoid (Ro 10-9359) resulted in clearing of the skin lesions in five patients with ichthyosis, four patients with Darier's disease and one patient with linear porokeratosis. No response to treatment was achieved in two patients with disseminated superficial actinic porokeratosis. Known side effects of retinoid treatment occurred in all patients in different intensity but disappeared when treatment was discontinued. Due to side effects (pruritus) treatment had to be discontinued only in one patient with Darier's disease and preexisting diabetes.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D007644:Darier Disease / Q000188:drug therapy*; D005050:Etretinate / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007057:Ichthyosis / Q000188:drug therapy*; D007642:Keratosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate
Behandlung hyperkeratotischer Dermatosen mit einem oralen, aromatischen Retinoid (Ro 10-9359).